Docking studies were conducted to propose a potential therapeutic strategy aimed at mitigating the increased expression of PIK3R1, thereby reducing inflammation severity in ARVC individuals. This evidence concerns the gene PIK3R1 and arrhythmogenic right ventricular cardiomyopathy.